Abstract: The present invention relates to a magnesium compound-supported nonmetallocene catalyst, which is produced by directly contacting a catalytically active metallic compound with a nonmetallocene ligand-containing magnesium compound, or by directly contacting a nonmetallocene ligand with a catalytically active metal-containing magnesium compound, through an in-situ supporting process. The process is simple and flexible. In the process, there are many variables in response for adjusting the polymerization activity of the catalyst, and the margin for adjusting the catalyst load or the catalyst polymerization activity is broad. The magnesium compound-supported nonmetallocene catalyst according to this invention can be used for olefin homopolymerization/copolymerization, in combination with a comparatively less amount of the co-catalyst, to achieve a comparatively high polymerization activity. Further, the polymer product obtained therewith boasts high bulk density and adjustable molecular weight distribution.

Abstract: The present invention relates to a process for preparing 3-dimethylaminopropylamine (DMAPA) by reacting 3-dimethylaminopropionitrile (DMAPN) with hydrogen in the presence of a catalyst, wherein the DMAPN used has a content of 2-(dimethylaminomethyl)glutaronitrile (DGN) of 300 ppm by weight or less, based on the DMAPN used. Furthermore, the present invention relates to mixtures of DMAPN and DGN, wherein the weight ratio of DMAPN to DGN is in the range from 1 000 000:5 to 1 000 000:250.

Abstract: A process for the preparation of free carboxylic acids including: A) preparation of carboxylic acid by a biological cell located in an aqueous medium with addition of an amine of formula (I) where R1, R2 and R3, independently of one another, are identical or different, branched or unbranched, optionally substituted hydrocarbon radicals or H; B) for cases where the added amine A) is water-soluble, addition of a water-insoluble amine of formula (I), where, in A) or B), a multiphase system is obtained and the corresponding ammonium carboxylate is formed from the water-insoluble amine and the carboxylic acid; C) removal of the water-insoluble phase; and D) heating of the water-insoluble phase with release of free carboxylic acid.

Abstract: A novel stilbene derivative is provided with motivation of providing a blue emissive material showing excellent color purity. The use of the stilbene derivative of the present invention allows the fabrication of a blue-emissive light-emitting element with excellent color purity. The invention also includes an electronic device equipped with a display portion in which the stilbene derivative is employed. The stilbene derivative of the present invention is represented by formula (1), in which Ar1 and Ar2 may form a 5-membered ring by being directly bonded to each other. In formula (1), A11 represents any one of substituents represented by general formulas (1-1) to (1-3). The variables shown in formula (1) and (1-1) to (1-3) are as defined in the specification.

Abstract: The invention relates to cyclopenta[c]pyrrole-2-carboxylate derivatives, to their preparation and to their therapeutic use.

Abstract: Thiazolyl oxime ethers and hydrazones of the formula (I), in which the symbols A, L1, L2, Y, W, X, R1, R2, R3, R4, R5, R6 and R7 have the meanings given in the description, and also agrochemically active salts thereof, and their use for controlling phytopathogenic harmful fungi, and also methods for controlling phytopathogenic harmful fungi and processes for preparing compounds of the formula (I).

Abstract: The present invention provides a cyclic amide derivative useful as a drug for treating thrombosis, which is represented by the formula (I): wherein R1 represents an optionally substituted cyclic hydrocarbon group or an optionally substituted heterocyclic group, W represents a bond or an optionally substituted divalent chain hydrocarbon group, a represents 0, 1, or 2, X1 represents an optionally substituted lower alkylene or an optionally substituted lower alkenylene, Y1 represents —C(O)—, —S(O)— or —S(O)2—, A represents a piperazine ring which may be further substituted or a piperidine ring which may be further substituted, X2 represents a bond or an optionally substituted lower alkylene, Y2 represents —C(O)—, —S(O)—, —S(O)2— or —C(?NR7)—, X3 represents an optionally substituted C1-4 alkylene or an optionally substituted C2-4 alkenylene, Z3 represents —N(R4)—, —O— or a bond, Z1 represents —C(R2) (R2?)—, —N(R2)—, etc., and Z2 represents —C(R3)(R3?)—, —N(R3)—, etc., or a salt thereof.

Abstract: Process for the production of at least one carbonylation product selected from acetic acid and methyl acetate, by carbonylating at least one carbonylatable reactant selected from methanol and reactive derivatives thereof with carbon monoxide in the presence of a catalyst. The catalyst is a mordenite which has been treated with an aqueous ammonium hydroxide solution and has a silica:alumina molar ratio of at least 10:1, and the reactive derivatives are selected from methyl acetate and dimethyl ether.

Abstract: The present invention relates to the field of catalytic hydrogenation and, more particularly, to the use of Ru complexes with bidentate ligands, having one amino or imino coordinating group and one phosphino coordinating group, in hydrogenation processes for the reduction of esters or lactones into the corresponding alcohol or diol respectively.

Abstract: The invention relates to sulfonamide compounds and methods for activating PKM2. The compounds and methods are useful in treating or preventing a disease or disorder selected from cancer, cell proliferative disorder, inflammatory disorder, metabolic disorder, and immune system disorder.

Abstract: The present invention relates to compounds with the formula (I), (II), (III) or (IV): wherein R1, R2, R3, R4, R5, R6, R7, X and Z are as defined herein, and also to pharmaceutical compositions comprising the compounds, as well as methods of use of the compounds for treatment of disorders associated with human 11-?-hydroxysteroid dehydrogenase type 1 enzyme and for the preparation of a medicament which acts on the human 11-?-hydroxysteroid dehydrogenase type 1 enzyme.

Abstract: Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers:

Abstract: Pyrandione, thiopyrandione and cyclohexanetrione compounds, which are suitable for use as herbicides.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: Pyridyldiamido transition metal complexes are disclosed for use in alkene polymerization to produce multimodal polyolefins.

Abstract: Stabilized benzyl phosphonic acid and naphthyl phosphonic acid analog compounds are effective in inhibiting the activity of autotaxin.

Abstract: The present invention relates to heterocyclic amide derivatives of Formula (I): Formula (I) wherein the variables are as defined in the specification. The present invention further relates to compositions comprising said heterocyclic amide derivatives of formula (I) and methods for using said heterocyclic amide derivatives of formula (I) for treating or preventing a disease or disorder related to the activity of a protein kinase, in particular, a proliferative disease, an anti-proliferative disorder, inflammation, arthritis, a neurological or neurodegenerative disease, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease or a fungal infection.

Abstract: The present invention is directed to certain Inidazole derivatives which are useful as modulators of Fatty Acid Amide Hydrolase (FAAH) and as FAAH imaging agents. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.

Abstract: The present invention relates to a process for the preparation of S-[2-[1-(2-ethylbutyl)cyclohexylcarbonylamino]-phenyl]2-methylthiopropionate which is useful as a pharmaceutically active compound.

Abstract: In one embodiment, the invention is to a process for purifying a by-product stream. The process comprises the step of providing a by-product stream comprising an ammonium salt, dimerized amide, and optionally water. The process further comprises the step of precipitating at least a portion of the dimerized amide in the by-product stream to form solid dimerized amide. The process further comprises the step of separating the solid dimerized amide from the by-product stream to form a treated by-product stream comprising less than 1 wt. % solid dimerized amide.